Granules India Ltd-$ — Q2 FY27 earnings call
Summary generated by AI from the official transcript Granules India Ltd-$ filed with BSE on 06 Oct 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Management presented Granules India's strategic transformation, outlining four growth engines: controlled substances, complex generics and early market opportunities, oncology, and peptide CDMO. The company reported that complex generics grew from 1% of revenue in FY20 to 33% in FY26, gross margin expanded by about 15 percentage points to 65% over four years, and EBITDA margin rose three percentage points to 22%. Management also discussed a planned organic capital expenditure of about 2,000 crore over the next three to four years to support these growth engines.
Numbers mentioned
Complex generics contribution to revenue: 33% (FY26)
p. 3
“This strategy has been demonstrated through the contribution of complex generics that increased from 1% of overall revenue in fiscal 20 to 33% of overall revenue in fiscal 26.”
Ms. Priyanka Chigurupati, page 3 of the filed PDF · View the filing
Gross margin: 65% (Over four years)
p. 8
“Over four years, gross margin expanded by about 15 percentage points to 65 percent and EBITDA margin by three percentage points to 22 percent.”
Mr. Mukesh Surana, page 8 of the filed PDF · View the filing
R&D investment as percent of revenue: 6% (Q1 FY27)
p. 8
“At the same time, R&D investment rose from about 3 percent of revenue a few years ago to 6 percent in Q1 FY27, improving the quality of sales growth.”
Mr. Mukesh Surana, page 8 of the filed PDF · View the filing
ROCE: 18%
p. 8
“While ROCE improved by about one percentage point year on year to 18 percent.”
Mr. Mukesh Surana, page 8 of the filed PDF · View the filing
Cash flow from operations as percent of EBITDA: 73% (Last four years)
p. 8
“Cash flow from operations averaged about 73 percent of our EBITDA over the last four years.”
Mr. Mukesh Surana, page 8 of the filed PDF · View the filing
Adderall XR market share: 29% (As of last month)
p. 6
“In Adderall XR, our share went from 5% in 2024 to 29% as of last month.”
Mr. Vijay Ramanavarapu, page 6 of the filed PDF · View the filing
Planned organic capex: 2,000 crore (Next three to four years)
p. 8
“We plan to invest about 2,000 crore in organic capital expenditure over the next three to four years, supporting complex generics pipeline, oncology pipeline, peptide CDMO, US operations, manufacturing and R&D infrastructure.”
Mr. Mukesh Surana, page 8 of the filed PDF · View the filing
ANDAs filed in oncology category: 2 products filed
p. 19
“Oncology, we have two products that are filed.”
Ms. Priyanka Chigurupati, page 19 of the filed PDF · View the filing
Total ANDAs filed: north of 95
p. 19
“We filed north of 95 ANDAs right now.”
Ms. Priyanka Chigurupati, page 19 of the filed PDF · View the filing
One-off abnormal expenses: close to 100 odd crores (Last full year)
p. 21
“In addition to that, you know, the failure to supply related and additional indirect cost because of, you know, additional remediation activities, and also, you know, some air freighting, which we had to do, all that if you put it together, it will be close to 100 odd crores, which are, you know, leakages, you know, not leakages, abnormal expenses, let's say.”
Mr. Mukesh Surana, page 21 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Peptide CDMO annual revenue run rate — approximately 50 million US dollar · three years
stated as an aspiration by Mr. Sanjay Kumar
p. 8
“We are targeting approximately 50 million US dollar in annual revenue run rate in three years from now as an intermediate milestone to get to and cross the threshold of 100 million revenue size in five years.”
Mr. Sanjay Kumar, page 8 of the filed PDF · View the filing
Peptide CDMO profitability — profitable · FY27
stated firmly by Mr. Sanjay Kumar
p. 8
“While our immediate financial priority is to become profitable this year, that is FY27, we have set out one intermediate and one long-term goal for ourselves.”
Mr. Sanjay Kumar, page 8 of the filed PDF · View the filing
US R&D filings per year — 10 to 15 products per year
stated as an aspiration by Ms. Priyanka Chigurupati
p. 5
“When it comes to R&D, the U.S. will always remain the anchor country where, going forward, we aim to file between 10 and 15 products per year, which will further be extended to Europe and rest of the world countries.”
Ms. Priyanka Chigurupati, page 5 of the filed PDF · View the filing
Specialty and institutional segment entry in US — first product launch · Fiscal 29
stated firmly by Ms. Priyanka Chigurupati
p. 4
“Our expanding portfolio will allow us to enter the specialty and institutional segments, with our first product expected to launch in Fiscal 29.”
Ms. Priyanka Chigurupati, page 4 of the filed PDF · View the filing
Oncology ANDA filing count — about 6 in pipeline · this year and early part of next year
stated firmly by Ms. Priyanka Chigurupati
p. 20
“In addition to that, we have about 6 in our pipeline that we'll be filing this year and the early part of next year.”
Ms. Priyanka Chigurupati, page 20 of the filed PDF · View the filing
Controlled substance new product launches — another 3 products · next 12 months
stated firmly by Mr. Vijay Ramanavarapu
p. 20
“We have another 3 products that we will be launching over the next several quarters over the next 12 months or so.”
Mr. Vijay Ramanavarapu, page 20 of the filed PDF · View the filing
Oncology ANDA run rate — between 10 and 15 US filings per year
stated as an aspiration by Ms. Priyanka Chigurupati
p. 19
“And going forward, we're looking to increase the run rate between 10 and 15 US filings per year.”
Ms. Priyanka Chigurupati, page 19 of the filed PDF · View the filing
Latin America and international market presence — meaningful presence · Fiscal 30
stated firmly by Ms. Priyanka Chigurupati
p. 5
“Fiscal 30, we intend to establish a meaningful presence across Latin America and other strategic international markets using a combination of B2B and B2C channels.”
Ms. Priyanka Chigurupati, page 5 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management confirmed they are actively and disciplined in looking for inorganic opportunities.
Answered by Dr. Krishna Prasad Chigurupati
Asked by Ahmed Madha: Given the stronger balance sheet and capex plans, is the company looking at inorganic opportunities?
p. 10
“Yes, we are always looking for inorganic opportunities and we have been very disciplined about it, not jumping into whatever comes our way and definitely we are very actively looking at it.”
Dr. Krishna Prasad Chigurupati, page 10 of the filed PDF · View the filing
CFO said near-term challenges exist but they are working with customers on pricing mechanisms, with growth and earnings quality improvement expected medium to long term.
Answered by Mr. Mukesh Surana
Asked by Ahmed Madha: How is the legacy business handling raw material cost pressure and pricing?
p. 10
“the near-term challenges are there, but we are proactively working with all our customer to see how we have a pricing mechanism to pass on, maybe some could be with a lag, but medium to long term, whatever the trajectory we have set out, the growth plans we have in terms of the product portfolio and investment plans, we will be in a consistent growth mode with an improvement in quality of earnings as well.”
Mr. Mukesh Surana, page 10 of the filed PDF · View the filing
Sanjay Kumar explained therapy choices are customer-partner driven and wider than GLP, and the $50 million figure is partly commercial success but mostly development and early supply revenue.
Answered by Mr. Sanjay Kumar
Asked by Ahmed Madha: What therapeutic areas are targeted in peptides, and is the $50 million target based on large commercial molecules?
p. 10
“a part of that is supposed to be based on the commercial successes. But a large part of that will still be a development and early supply, especially in the context of the mid stage 50 million stage that you asked about.”
Mr. Sanjay Kumar, page 10 of the filed PDF · View the filing
CFO said the capex plan is broad-based with a significant portion allocated across peptide CDMO, complex generics, and oncology, declining to give exact numbers.
Answered by Mr. Mukesh Surana
Asked by Adi: Can the 2,000 crore capex be broken down across complex generics, oncology, peptide CDMO, US operations?
p. 12
“significant portion is, of course, will be going into three buckets largely the Peptide CDMO, complex as well as oncology and then rest.”
Mr. Mukesh Surana, page 12 of the filed PDF · View the filing
Sanjay Kumar said decisions depend on clinical success outcomes on the innovator side, with fee-for-service income providing some buffer against failures.
Answered by Mr. Sanjay Kumar
Asked by Adi: What milestones would make the company pause or cut peptide spending?
p. 12
“it's largely depending on the clinical success outcome on the innovator side. For us we ride with them, there would be successes and that those successes will bring in the lumpy upside.”
Mr. Sanjay Kumar, page 12 of the filed PDF · View the filing
Vijay said Granules was satisfied with the quota received and that allocation increases yearly due to track record and compliance.
Answered by Mr. Vijay Ramanavarapu
Asked by Sameer Baisiwala: How did the recent DEA quota allocation go for controlled substances?
p. 13
“Granules were satisfied with the quota that we received.”
Mr. Vijay Ramanavarapu, page 13 of the filed PDF · View the filing
Priyanka said all committed CAPAs have been completed and they are in continuous correspondence with the FDA awaiting the re-inspection.
Answered by Ms. Priyanka Chigurupati
Asked by Sameer Baisiwala: What is the status of the Gaggilapur facility with respect to US FDA re-inspection?
p. 14
“we've finished everything that we committed to the FDA, we've completed--- we've taken over 100 CAPAs and we have completed all the activities related to the CAPAs. We've been in continuous correspondence with the FDA and we expect them to come anytime now.”
Ms. Priyanka Chigurupati, page 14 of the filed PDF · View the filing
Sanjay Kumar described revenue split across development, commercial, and CDMO partnership work without disclosing exact molecule counts.
Answered by Mr. Sanjay Kumar
Asked by Dhara Ganatra: How many molecules and at what stage is Senn Tides working on, and does it have commercial capability?
p. 15
“A third of our revenue which is roughly as of last year $20 million is based on development projects.”
Mr. Sanjay Kumar, page 15 of the filed PDF · View the filing
Priyanka explained their selective product criteria and proven filing capability, while CMD added the company has stepped up R&D capabilities.
Answered by Ms. Priyanka Chigurupati
Asked: What gives Granules confidence of winning sole FTFs given fewer such opportunities exist industry-wide, and what differentiates them in oncology?
p. 16
“Within the overall basket we pick about 10 to 20% of the products are sole first-to-file and the rest are divided among several segments.”
Ms. Priyanka Chigurupati, page 16 of the filed PDF · View the filing
Vijay described strict internal controls, digitalized compliance tools, customer vetting, and a flawless audit track record.
Answered by Mr. Vijay Ramanavarapu
Asked by Aejas Lakhani: How does Granules manage DEA compliance risk in controlled substances?
p. 18
“overall, I think our track record speaks for itself in the nine to ten years that we've had the facility we've had essentially flawless DEA audits with no observations.”
Mr. Vijay Ramanavarapu, page 18 of the filed PDF · View the filing
CFO explained that rising R&D spend and increased manufacturing costs from vertical integration have offset gross margin gains, with partial translation expected going forward.
Answered by Mr. Mukesh Surana
Asked by Sameer Baisiwala: Why hasn't gross margin expansion translated into EBITDA margin expansion?
p. 19
“my gross margin improves, my operating expense also improves. So, to that extent, you know, we have not fully gotten to full translation of 15% but there will be some translation of 15% into the EBITDA going forward.”
Mr. Mukesh Surana, page 19 of the filed PDF · View the filing
CFO said a significant and fairly higher than 50% portion is fixed, without giving an exact number.
Answered by Mr. Mukesh Surana
Asked by Naman Bagrecha: What portion of above-EBITDA expenses are fixed versus variable?
p. 21
“Fairly higher than 50%. I will not be able to give you a number, unfortunately, Naman.”
Mr. Mukesh Surana, page 21 of the filed PDF · View the filing
Risks flagged
Raw material cost pressure and shortages in legacy business products
p. 10
“there has been a lot of disruption in terms of some shortages in some products we hear in developed markets, for example, ibuprofen and there will be RM cost pressure considering the way global environment is.”
Mr. Ahmed Madha, page 10 of the filed PDF · View the filing
DEA regulatory compliance risk in controlled substances
p. 17
“the DEA regulations are very stringent and any lapses in compliance could have a very high adverse impact for us on the CS segment.”
Mr. Aejas Lakhani, page 17 of the filed PDF · View the filing
Peptide clinical development failures
p. 12
“there would be failures that clinical program doesn't go through from stage one to stage two and we live with that.”
Mr. Sanjay Kumar, page 12 of the filed PDF · View the filing
Litigation uncertainty preventing disclosure of launch timelines for some controlled substance products
p. 14
“these are products that some several of the products that you mentioned we've disclosed this will be under litigation so it's not appropriate right now to name the launch timelines but this will happen over a certain time frame for each product, every product is unique.”
Mr. Vijay Ramanavarapu, page 14 of the filed PDF · View the filing
One-off remediation and failure-to-supply costs impacting earnings
p. 21
“we have incurred close to 60 odd crores on the USFDA remediation consultancy related cost.”
Mr. Mukesh Surana, page 21 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.
Continue reading
More Q2 FY27 earnings calls, in alphabetical order